Bile Duct Cancer Market Size by 2023; Teva Pharmaceutical, Sanofi, Fresenius Kabi AG, Mylan N.V. and More

The Global Bile Duct Cancer Market is expected to grow at an approximate CAGR of 9.2% during the forecast period 2018-2023.

Bile duct cancer is a rare type of neoplasm in which epithelial cells of the bile duct are mutated and show epithelial differentiation. In 2014, according to the National Cancer Institute, there were an estimated 66,771 cases of intrahepatic bile duct cancer in the United States. Moreover, the disease is expected to cause 28,920 deaths by the end of 2017 accounting for 4.8% of all cancer deaths.

Death rates have been rising on average 2.6% each year over 2005-2014. Such an increasing prevalence of the bile duct cancer will boost the market during the forecasted period. Moreover, rising healthcare expenditures, increasing awareness for the disease and investments in the R&D for treatment procedures is fuelling the market. However, high cost of treatment and related side effects along with low healthcare expenditures in the developing economies is expected restrain the market during the forecasted period.

Regional Analysis

The Americas dominates the global bile duct cancer market owing to a well-developed healthcare sector. Apart from this, increasing number of patients, increasing healthcare expenditure have boosted the growth of the market in the Americas. According to the Centers for Disease Control and Prevention, U.S. health care spending in 2015, reached $3.2 trillion or $9,990 per person which accounted for 17.8% of the total GDP.

Access Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/4741 .

Europe is the second largest bile duct cancer market, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development drives the European market.

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China, and presence of huge opportunity in the market. According to Indian Brand Equity Fund, the per capita healthcare expenditure in India is estimated to grow at a CAGR of 5% during 2008-15 and reach USD 68.6 by 2015.

On the other hand, the Middle East & Africa has the least share in the global bile duct cancer market due to the presence of poor economy especially in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.

Key players for global bile duct cancer market

The key players for the global bile duct cancer market are Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Europe), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd. (Middle East), Eli Lilly and Company. (U.S.), Sanofi (Europe), Fresenius Kabi AG (Europe), Mylan N.V. (U.S.), and others.

Get Attractive Discount @ https://www.marketresearchfuture.com/check-discount/4741 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.